Beating Cervical Cancer

Fahey, Jonathan
October 2005
Forbes Asia;10/31/2005, Vol. 1 Issue 6, p16
The article reports on the results of the trial for a vaccine that could prevent human papilloma virus (HPV) which causes genital warts and cervical cancer conducted by Merck. 100 percent of women who received the vaccine were protected against HPV. An estimated 20 million men and women in the U.S. acquired HPV through sex. The company plans to apply for regulatory approval for the vaccine.


Related Articles

  • Success for Cervical Cancer Vaccine. Grose, Simon // Australasian Science;Aug2007, Vol. 28 Issue 7, p39 

    The article discusses the findings of clinical trials of Gardasil vaccine from Merck to protect young women against infection by four strains of human papillomavirus (HPV) linked to cervical cancer. A study found that there are possible linkages between cancers of the upper throat and HPV...

  • Sorry Kids, Another Shot!  // State Legislatures;Jan2007, Vol. 33 Issue 1, p7 

    The article reports on Merck's Gardasil and GlaxoSmithKline's Cervarix vaccines to fight human papilloma virus (HPV) causing cervical cancer and genital warts. The U.S. Food and Drug Administration approved Gardasil vaccine for females between 9 and 26. The Centers for Disease Control recommends...

  • Merck's Lybrand Plays It Cool In Midst of Hot Controversy. Edwards, Jim // Brandweek;4/16/2007, Vol. 48 Issue 16, p5 

    The article examines the controversy surrounding Gardasil, which is a vaccine for HPV, genital warts and cervical cancer that is administered to teenage girls. The article reports that Merck, the company that distributes the drug, first ran into controversy when it began a lobbying campaign to...

  • GARDASIL: WHAT YOU NEED TO KNOW ABOUT THE HPV Vaccine.  // Network Magazine of the Canadian Women's Health Network;Spring/Summer2007, Vol. 9 Issue 3/4, p14 

    The article offers information about the Gardasil, a human papillomavirus (HPV) vaccine approved for use in Canada and the U.S. It is noted that this specific vaccine prevents infection from HPV types 6 and 11, which cause genital warts, and HPV types 16 and 18, which cause cancer. However, the...

  • Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. Marty, Rémi; Roze, Stéphane; Bresse, Xavier; Largeron, Nathalie; Smith-Palmer, Jayne // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background: HPV is related to a number of cancer types, causing a considerable burden in both genders in Europe. Female vaccination programs can substantially reduce the incidence of HPV-related diseases in women and, to some extent, men through herd immunity. The objective was to estimate the...

  • Cost-effectiveness of different human papillomavirus vaccines in Singapore. Lee, Vernon J.; Tay, Sun Kuie; Teoh, Yee Leong; Tok, Mei Yin // BMC Public Health;2011, Vol. 11 Issue 1, p203 

    Background: Human papillomavirus (HPV) vaccines are widely available and there have been studies exploring their potential clinical impact and cost-effectiveness. However, few studies have compared the cost-effectiveness among the 2 main vaccines available - a bivalent vaccine against HPV 16/18,...

  • Epidemiological Aspects of Genital Warts in Romania - a 2012 Retrospective Survey. SALAVASTRU, Carmen Maria; NICULESCU, Mihaela Cristina; ZOTA, Alexandra; NICOLA, Gheorghe; MORARIU, Horia Silviu; SOLOVAN, Caius; PATRASCU, Virgil; POPOVICI, Georgeta; VLADUTA, Raluca; PANDURU, Mihaela; TIPLICA, George-Sorin // Maedica - a Journal of Clinical Medicine;2014, Vol. 9 Issue 2, p144 

    Objectives: Genital infection with human papillomavirus (HPV) has become one of the most frequently viral sexually transmitted diseases. The infection may remain asymptomatic, may take the form of external genital warts and may give raise to cervical cancers. The aim of this study was to assess...

  • A QUIET INFECTION. Fernández, Sara; Zuellig, Alissa // Hispanic;May2007, Vol. 20 Issue 4, p26 

    The article reports on the discovery of a new vaccine called Gardasil to prevent diseases caused by human papillomavirus (HPV). According to the article, although Gardasil, manufactured by the pharmaceutical company Merck, targets four types of HPV that together cause 70 percent of cervical...

  • FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and Guidance from the Advisory Committee on Immunization Practices (ACIP).  // MMWR: Morbidity & Mortality Weekly Report;5/28/2010, Vol. 59 Issue 20, p630 

    The article provides information on the licensure of quadrivalent human papillomavirus vaccine (HPV4), Gardasil from Merck & Co. Inc. by the U.S. Food and Drug Administration (FDA) for use in males to prevent genital warts caused by HPV 6 and HPV 11. The Advisory Committee on Immunization...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics